Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 128 participants.

Also called NCT07932145

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 128 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07932145
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07932145. Randomized; single masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension
Acronym
EMERALD
Condition
Hypertension (HTN)
Condition
Low-Renin Essential Hypertension
Intervention (Drug)
Eplerenone
Intervention (Drug)
Telmisartan
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct07932145
Content hash
9ac62d7cba2b05e4860400b2ac2f10dcd8ca5421572259188cfb1790f5da8afb